The incidence of type 2 amiodarone-induced thyrotoxicosis (AIT) is increasing. A new study provides evidence that glucocorticoid therapy is safe, effective and associated with prompt restoration of euthyroidism in previously untreated type 2 AIT. The outcome of initial combined glucocorticoid and thionamide therapy can also help differentiate between type 1 and type 2 AIT.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Amiodaron-induzierte Thyreopathien
Journal für Klinische Endokrinologie und Stoffwechsel Open Access 02 September 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Han, T., Williams, G. R. & Vanderpump, M. P. J. Benzofuran derivatives and the thyroid. Clin. Endocrinol. (Oxf.) 70, 2–13 (2009).
Martino, E., Bartalena, L., Bogazzi, F. & Braverman, L. E. The effects of amiodarone on the thyroid. Endocr. Rev. 22, 240–254 (2001).
Basaria, S. & Cooper, D. S. Amiodarone and the thyroid. Am. J. Med. 118, 706–742 (2005).
Franklyn, J. A. & Gammage, M. D. Treatment of amiodarone-associated thyrotoxicosis. Nat. Clin. Pract. Endocrinol. Metab. 3, 662–666 (2007).
Tanda, M. L. et al. Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. Clin. Endocrinol. (Oxf.) 69, 812–818 (2008).
Bogazzi, F. et al. Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study. J. Clin. Endocrinol. Metab. 94, 3757–3762 (2009).
Bogazzi, F. et al. Glucocoticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. J. Clin. Endocrinol. Metab. 92, 556–562 (2007).
Bogazzi, F. et al. Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clin. Endocrinol. (Oxf.) 67, 533–537 (2007).
Loy, M. et al. Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Acta Radiol. 48, 628–634 (2007).
Piga, M. et al. The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Eur. J. Endocrinol. 159, 423–429 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Vanderpump, M. Use of glucocorticoids in amiodarone-induced thyrotoxicosis. Nat Rev Endocrinol 5, 650–651 (2009). https://doi.org/10.1038/nrendo.2009.218
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2009.218
This article is cited by
-
Amiodaron-induzierte Thyreopathien
Journal für Klinische Endokrinologie und Stoffwechsel (2020)